Disease Information & Support


The Word:


Generic name Azacitidine
Pronunciation ay-za-SITE-i-deen
Brand name(s), other common name(s) Vidaza®
Drug type  Hypomethylating (Demethylating) agent
How the drug is given Subcutaneous (SC) injection or intravenously (IV)

Azacitidine is FDA approved to treat people who have certain myelodysplastic syndrome subtypes and chronic myelomonocytic leukemia.

Side effects needing medical attention: Black, tarry stools; bladder pain; bleeding gums; blood in urine or stool; cloudy urine; body aches or pain; burning or stinging of skin; chest pain or tightness in the chest; chills; ear, nose or chest congestion; cough; diarrhea; difficulty breathing, shortness of breath or wheezing; difficulty swallowing; dizziness; fast heartbeat; fever; frequent urge to urinate; headache; hives; hoarseness; itching; loss of voice or voice changes; lower back or side pain; muscle aches; nausea or vomiting; pain or tenderness around eyes and cheekbones; painful cold sores or blisters on lips, nose, eyes or genitals; painful or difficult urination; pain, redness, swelling, tenderness or warmth on skin; pale skin; pinhead-sized red spots on skin; puffiness or swelling of the eyelids or around the eyes, face, lips or tongue; rapid heartbeat; sore throat; sores, ulcers, or white spots on lips or in mouth; swollen glands; tender, swollen glands in neck; troubled breathing with exertion; unusual bleeding or bruising; unusual tiredness or weakness. 


For information on how to manage the costs of drug therapy, please see Financial Matters and Prescription Drug Coverage, or to speak with an Information Specialist, call (800) 955-4572.

last updated on Tuesday, April 09, 2013